FDA roadmap to reducing animal testing – A new regulatory era

Since the FDA outlined a 3–5-year ambition to make animal studies the exception rather than the rule, the use of New Approach Methodologies (NAMs) are gaining widespread regulatory adoption.

Find out more about the large number of resources BioIVT provides for NAM submissions, and how it offers a suite of human-derived biospecimens and services to support the initiative to end animal testing.